NEWER OPHTHALMIC IN SITU GEL OF MOXIFLOXACIN HYDROCHLORIDE: OPTIMIZATION USING BOX BEHNKEN STATISTICAL DESIGN
Keywords:Moxifloxacin hydrochloride (MH), Box-Behnken Design, Gelrite, HPMC K4M, Tamarind gum
Objective: The present research work aims at describing the formulation and evaluation of the ocular delivery system of moxifloxacin hydrochloride (MH) based on the concept of ion sensitive in situ gelations.
Methods: In situ gel was prepared by a hot method using 0.6% of gelrite, 0.25% hydroxypropylmethylcellulose (HPMC K4M) and 0.023% tamarind gum as bioadhesive polymers for sustained drug release. Optimization was done by Box Behnken Design with different concentration of gelrite (X1), HPMC K4M (X2) and tamarind gum (X3) as independent variables. In situ gel was optimized based on mucoadhesion index (Y1), Gel strength (Y2) and in vitro drug release (Y3). Influence of the quantitative variable on the dependent variable was predicted by a polynomial equation.
Results: Infrared spectroscopy excluded any interaction between drug and excipients. The selected independent variables significantly influenced the responses and were able to sustain the drug release. The prepared gel with a pH of 6.8 to 7.4 exhibited non-newtonian flow with no ocular irritation. The formulation remained stable with no change in pH and viscosity after 30 d of stability study.
Conclusion: Thus, moxifloxacin hydrochloride (MH) in situ gel is a viable alternative to a conventional delivery system with the properties of sustained drug release, prolonged ocular retention, and improved corneal penetration.
Ludwig A, van Haeringen NJ, Bodelier VM, Van Ooteghem M. Relationship between precorneal retention of viscous eye drops and tear fluid composition. Int Ophthalmol 1992; 16:23–6.
Liu L, Tiffany J, Dang Z, Dart JKG, Watson SL, Daniels JT. Nourish and nurture: development of an ocular nutrient lubricant. Investig Ophthalmol Vis Sci 2009;50:2932–9.
Release C, Situ IN, Moxifloxacin F, Drug O. Controlled Release in Situ Forming Moxifloxacin; 2010.
Katiyar S, Pandit J, Mondal RS, Mishra AK, Chuttani K, Aqil M. In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma. Carbohydr Polym 2014;102:117–24.
Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int J Pharm 2013;443:293–305.
Maheswaran A, Padmavathy J, Nandhini V, Saravanan D, Angel P. Formulation and evaluation of floating oral in situ gel of diltiazem hydrochloride. Int J Appl Pharm 2017;9:1–4.
Kassab HJ, Thomas LM, Jabir SA. Development and physical characterization of a periodontal bioadhesive gel of gatifloxacin. Int J Appl Pharm 2017;9:10–5.
Ahmed VA, Goli D. Development and characterization of in situ gel of xanthan gum for the ophthalmic formulation containing brimonidine tartrate. Asian J Pharm Clin Res 2018;11:277-84.
Rathore KS. Development and in vivo in vitro characterizations of timolol maleate in-situ gels. Int J Pharma Bio Sci 2011;2:248–63.
Liu Z, Li J, Nie S, Liu H, Ding P, Pan W. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 2006;315:12–7.
Gupta SK, Singhvi IJ. Sustained ophthalmic delivery of moxifloxacin hydrochloride from an pH-triggered in situ gelling system. Res J Pharm Technol 2012;5:1538–42.
Ibrahim HM, Ahmed TA, Hussain MD, Rahman Z, Samy AM, Kaseem AA. Development of meloxicam in situ implant formulation by quality by design principle. Drug Dev Ind Pharm 2014;40:66–73.
Sulaiman HT, Kassab HJ. Preparation and characterization of econazole nitrate inclusion complex for ocular delivery system. Int J App Pharm 2018;10:175-81.
Srivastava R, Srivastava S, Singh SP. Thermoreversible in-situ nasal gel formulations and their pharmaceutical evaluation for the treatment of allergic rhinitis containing extracts of moringa olifera and embelia ribes. Int J App Pharm 2017;9:16-20.
El-Kamel A, El-Khatib M. Thermally reversible in situ gelling carbamazepine liquid suppository. Drug Delivery J Delivery Target Ther Agents 2006;13:143–8.
He W, Guo X, Feng M, Mao N. In vitro and in vivo studies on ocular vitamin a palmitate cationic liposomal in situ gels. Int J Pharm 2013;458:305–14.
Di Colo G, Zambito Y, Zaino C, Sans M. Selected polysaccharides at the comparison for their mucoadhesiveness and effect on the precorneal residence of different drugs in the rabbit model. Drug Dev Ind Pharm 2009;35:941–9.
Gan L, Gan Y, Zhu C, Zhang X, Zhu J. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine a: in vitro and in vivo results. Int J Pharm 2009;365:143–9.
Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite®: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on the bioavailability of timolol. Int J Pharm 1989;57:163–8.
Uccello-Barretta G, Nazzi S, Zambito Y, Di Colo G, Balzano F, Sansò M. Synergistic interaction between TS-polysaccharide and hyaluronic acid: implications in the formulation of eye drops. Int J Pharm 2010;395:122–31.
Bhowmik M, Das S, Chattopadhyay D, Ghosh LK. Study of thermo-sensitive in-situ gels for ocular delivery. Sci Pharm 2011;79:351–8.
Srinivasan B, Ganta A, Rajamanickam D, Veerabhadraiah BB, Varadharajan M. Evaluation of tamarind seed polysaccharide as a drug release retardant. Int J Pharm Sci Rev Res 2011;9:27–31.
Mohan EC, Kandukuri JM, Allenki V. Preparation and evaluation of in-situ-gels for ocular drug delivery. J Pharm Res 2009;2:1089–94.